[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seroma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,70,98,134,168,188,217,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100648262","hernia-sac-flap-coverage-of-mesh-in-bony-edged-ventral-hernia-repair-100648262",false,"NCT07720154","Hernia Sac Flap Coverage of Mesh in Bony-Edged Ventral Hernia Repair","Sac-Flap Peritonealization of Mesh in Bony-Edged Ventral Hernias: A Randomized Controlled Trial","PERI-SAC","Inclusion Criteria:\n\n* Age 18 years or older.\n* Elective open repair planned for a complex ventral hernia (primary or incisional) in which at least one margin of the fascial defect is formed by bone - that is, a subxiphoid or costal-margin, suprapubic, or iliac or lumbar location - confirmed on cross-sectional imaging (CT or MRI) and at operation.\n* A hernial sac of sufficient quality and surface area to raise a pedicled flap adequate to cover the planned mesh, as judged at operation.\n* Planned retromuscular (sublay) synthetic mesh repair, with or without posterior component separation (transversus abdominis release).\n* Able to give written informed consent and to attend scheduled follow-up for 12 months.\n\nExclusion Criteria:\n\n* Emergency or urgent operation (incarceration with strangulation, obstruction, or perforation).\n* Active intra-abdominal infection, or a contaminated or dirty operative field (CDC wound class III-IV) at the time of randomization.\n* Planned use of biologic or composite intraperitoneal mesh, or a bridged (non-fascial-closure) repair as the primary plan.\n* Hernial sac absent, destroyed, densely scarred, or too small to raise a viable covering flap.\n* Concurrent bowel resection or stoma creation expected to alter the wound-contamination class.\n* ASA physical status V.\n* Life expectancy less than 12 months, or active malignancy under treatment with anticipated short survival.\n* Pregnancy.\n* Inability or unwillingness to provide informed consent or to comply with follow-up","ALL","18 Years","75 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","This trial asks whether covering the inner, bowel-facing surface of a hernia mesh with a flap of the patient's own hernia sac improves healing after repair of a complex ventral (abdominal wall) hernia in which one edge of the defect is bone - for example hernias next to the breastbone and ribs, above the pubic bone, or at the iliac crest.\n\nIn these \"bony-edged\" hernias the mesh is both hardest to fix and hardest to cover. There is no fascia on the bony side for the surgeon to stitch the mesh to, and the lining layer of the abdomen cannot be closed underneath the mesh because the plane that carries it stops at the bone. The mesh may therefore be left in contact with the bowel, which can lead to dense adhesions, mesh erosion, chronic pain and, rarely, a fistula.\n\nNormally the hernia sac - the thin membrane that lines the hernia - is cut away and discarded. In this trial the surgeon instead preserves it as a living, blood-supplied flap, rotates it underneath the mesh, and stitches it in place as a new lining layer that separates the mesh from the bowel and covers the bony edge. The technique uses only the patient's own tissue: no extra mesh, no donor site and no added cost.\n\nOne hundred and eighty adults undergoing planned (non-emergency) open repair of a bony-edged complex ventral hernia will be randomly assigned in equal numbers to one of two groups: standard retromuscular (sublay) mesh repair with the added sac flap (90 participants), or standard retromuscular mesh repair alone, with the sac handled in the conventional way (90 participants). Every other step of the operation is the same in both groups.\n\nThe main question is whether the sac flap reduces the number of participants who develop any wound or mesh problem in the first 30 days after surgery. This is measured as a composite called a surgical site occurrence, which includes wound infection, seroma, haematoma, skin or soft-tissue death, wound breakdown, mesh exposure and fistula. The trial also compares complications needing a drainage or operative procedure, hernia recurrence at 12 months, overall complication severity, operating time, blood loss, hospital stay, readmission, reoperation, pain, quality of life and death.\n\nParticipants, ward and clinic staff, the doctors who assess the wounds, the radiologist who reads the follow-up scans and the trial statistician will not know which operation was performed; only the operating surgeon will. The group assignment is revealed only during the operation, after the surgeon has confirmed that the defect truly has a bony edge and that the sac is suitable for a flap. Participants are followed for 12 months.",[28,29,30,31,32,33,34],"Incisional Hernia","Abdominal Hernia","Complex Ventral Hernia","Surgical Site Infection","Seroma","Postoperative Complications","Ventral Hernia",[36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"ventral hernia","incisional hernia","complex abdominal wall reconstruction","bony-edged hernia","subxiphoid hernia","suprapubic hernia","lumbar hernia","iliac crest hernia","hernial sac","sac flap","peritonealization","neo-peritoneum","autologous tissue coverage","retromuscular mesh","sublay mesh repair","transversus abdominis release","posterior component separation","surgical site occurrence","mesh-visceral interface","mesh erosion","hernia recurrence","RECRUITING","2026-08-16",{"date":60,"type":61},"2026-08-18","ACTUAL",{"date":63,"type":61},"2026-08-15",{"date":65,"type":22},"2028-08-15",{"name":67,"class":68},"Minia University","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":69},"100631233","phase-2-doxycycline-use-in-post-operative-seromas-100631233","NCT07498010","Doxycycline Use in Post-Operative Seromas","The Role of Doxycycline in the Management of Postoperative Seromas: A Pilot Study","Inclusion Criteria:\n\n* Patient with seroma formation following orthopedic procedure\n* \\>18 years old\n* Willing and able to provide informed consent\n* Pre-operative imaging (US, CT) demonstrating seroma formation\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Age \\\u003C18 years\n* Known allergy to tetracyclines\n* Significant hepatic or renal dysfunction (Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) \\>3× Upper Limit of Normal (ULN), Creatinine Clearance (CrCl \\\u003C30 mL\u002Fmin)\n* History of photosensitivity or photodermatosis\n* Concurrent isotretinoin or retinoid therapy\n* Current use of anticoagulants or immunosuppressants\n* Active GI ulceration or esophageal disease\n* Any condition likely to impair adherence or drug absorption (e.g., malabsorption syndromes)",{"count":78,"type":22},10,[80],"PHASE2","Seromas are collections of serous fluid that can develop following surgical procedures and may persist as fibrous-lined pseudocysts if not adequately treated. In orthopedic surgery, particularly after arthroplasty, seromas can impair wound healing, increase pain, and limit postoperative rehabilitation, potentially compromising patient recovery. Current treatment strategies including compression, percutaneous aspiration, and repeat surgical intervention have variable success, and aspiration carries the risk of introducing bacteria into an otherwise sterile fluid collection. Sclerotherapy has been proposed as an alternative strategy to induce fibrosis within the cavity and eliminate the potential space. Doxycycline, a tetracycline antibiotic commonly used for pleurodesis, has demonstrated sclerosing properties through mechanisms including mesothelial cell destruction, inhibition of fibrinolysis, and stimulation of fibroblast activity. While doxycycline sclerotherapy has shown success in treating conditions such as Morel-Lavallée lesions and has been described in isolated orthopedic case reports, its role in managing postoperative seromas after arthroplasty remains poorly studied. Further investigation is needed to determine whether doxycycline injection may serve as a safe and effective treatment to reduce persistent seromas and the need for additional interventions in orthopedic patients.",[32],[84,85,86,87,88],"seroma","doxycycline","post operative complications","sclerotherapy","fibrosis induction","2026-07-07",{"date":91,"type":61},"2026-07-09",{"date":93,"type":61},"2026-05-31",{"date":95,"type":22},"2027-10-01",{"name":97,"class":68},"University of Miami",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":69},"100646632","steri-strip-application-versus-standard-wound-closure-for-cesarean-section-incisions-100646632","NCT07686913","Steri-Strip Application Versus Standard Wound Closure for Cesarean Section Incisions","A Randomized Prospective Trial Comparing Steri-Strip Application Versus Standard Wound Closure for Cesarean Section Incisions","STRIP-CS","Inclusion Criteria:\n\n* Female patients age 18 years or older\n* Pregnant patients undergoing cesarean delivery at Riverside University Health System Medical Center (RUHS)\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to Steri-Strip™ materials or adhesives\n* Inability or unwillingness to provide informed consent\n* Anticipated inability to complete the 30-day postpartum follow-up evaluation","FEMALE",{"count":108,"type":22},610,[25],"This study is evaluating whether Steri-Strips® provide additional benefits when used after cesarean section (C-section) surgery. Steri-Strips are adhesive strips that are commonly placed over a surgical incision to provide support while the wound heals. At our hospital, Steri-Strips are routinely used after C-sections in addition to standard wound closure techniques, although they are not considered part of the standard recommended closure method.\n\nResearchers want to determine whether adding Steri-Strips actually reduces wound complications such as infection, fluid collection under the skin, or reopening of the incision. Previous studies have shown mixed results, with some suggesting little difference in wound healing outcomes while others reported differences in scar appearance. Steri-Strips may also increase costs, add time to the surgery, and occasionally cause skin irritation or allergic reactions.\n\nParticipants in this study will be randomly assigned to one of two groups. One group will receive standard cesarean wound closure with Steri-Strips, while the other group will receive standard wound closure without Steri-Strips. Researchers will compare wound healing, complications, patient outcomes, and costs between the two groups.\n\nThe goal of this study is to determine whether Steri-Strips improve recovery after cesarean delivery and whether their routine use is beneficial and cost-effective. The findings may help guide future recommendations for cesarean wound care and improve outcomes for patients undergoing C-section delivery.",[112,31,113,32],"Cesarean Section","Wound Dehiscence",[112,115,116,117,118,119,31,113,32,120,121,122,123,124,125],"Cesarean Delivery","C-Section","Steri-Strips","Skin Closure","Wound Closure","Postoperative Wound Complications","Obstetric Surgery","Incision Management","Surgical Wound Healing","Maternal Morbidity","Randomized Controlled Trial","2026-06-29",{"date":89,"type":61},{"date":129,"type":22},"2026-06",{"date":131,"type":22},"2027-12",{"name":133,"class":68},"Riverside University Health System Medical Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100642717","prophylactic-use-of-cinpwt-in-gynecologic-laparotomy-100642717","NCT07645547","Prophylactic Use of ciNPWT in Gynecologic Laparotomy","Implementation of Prophylactic Negative Pressure Wound Therapy (ciNPWT) in High-Risk Patients in Gynecologic Oncology: A Prospective Feasibility Study and Nested Qualitative Analysis","Inclusion Criteria:\n\n* Adult female patients scheduled for planned abdominal surgery for gynecologic or gynecologic-oncologic indications.\n\nIdentification as \"high-risk\" for wound healing complications based on a clinical risk screening at admission.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Failure to provide informed consent.",{"count":142,"type":22},30,[25],"This is a prospective, open-label, non-randomized interventional feasibility study with a nested qualitative analysis. The study exploratively verifies the feasibility of targeted prophylactic closed incision negative pressure wound therapy (ciNPWT) in clinical practice for patients with a high predicted risk of wound healing complications and compares the 30-day incidence of postoperative complications with standard dressing.\n\nParticipants will:\n\n* Get ciNPWT or standard dressing after planned laparotomy\n* Answer the questionairs about qualite of life\n* Will visit the clinic 30 days after surgery to see the final result",[146,147,32,148,149],"Surgical Site Infection (SSI)","Wound Healing Complication","Hematoma","Dehiscence",[151,152,153,154,155,156,157],"ciNPWT","laparotomy","surgical site infection","SSI","feasibility","PROMs","ASEPSIS","NOT_YET_RECRUITING","2026-06-11",{"date":161,"type":61},"2026-06-12",{"date":163,"type":22},"2026-07",{"date":165,"type":22},"2028-12",{"name":167,"class":68},"University Hospital Hradec Kralove",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":69},"100597614","management-of-seroma-after-posterior-lumbar-spine-decompression-100597614","NCT07060781","Management of Seroma After Posterior Lumbar Spine Decompression","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both sexes.\n* Patients undergoing elective posterior lumbar spine decompression.\n\nExclusion Criteria:\n\n* History of previous lumbar spine surgery.\n* Active spinal infection, trauma, or malignancy.\n* Severe medical comorbidities that contraindicate surgery or influence wound healing (e.g., uncontrolled diabetes, immunosuppression, severe cardiovascular disease).\n* Patients unfit for general anesthesia.",{"count":175,"type":22},50,"OBSERVATIONAL","The aim of this study is to evaluate the clinical presentation and management strategies of seroma formation following posterior lumbar spine decompression.",[32,179],"Lumbar Spine Decompression","2025-07-19",{"date":182,"type":61},"2025-07-22",{"date":180,"type":61},{"date":185,"type":22},"2025-12-30",{"name":187,"class":68},"Kafrelsheikh University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":69},"100515275","phase-2-outcomes-of-high-volume-saline-irrigation-vs-povidone-iodine-solution-cleaning-of-iowi-in-preventing-ssis-in-emergency-laparotomies-100515275","NCT05989386","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of IOWI in Preventing SSIs in Emergency Laparotomies","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of Intraoperative Incision Wound in Preventing Surgical Site Infections in Emergency Laparotomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Patients undergoing emergency laparotomy under the care of surgical-6 unit of Dr. Ruth K. M. Pfau Civil Hospital Karachi\n\n  * The age of patients should be between 18-60 years old.\n\nExclusion Criteria:\n\n* Diabetic patients\n* Immune-suppressed patients\n* Patients taking steroids\n* Patients undergoing chemo-radiotherapy.\n* Pregnant females\n* Previous abdominal surgery within the last 30 days.\n* Presence of concurrent abdominal wall infections.\n* Trauma Laparotomies\n* Large Bowel perforations","60 Years",{"count":197,"type":22},200,[80,199],"PHASE3","The goal of this clinical trial is to compare the outcomes of High-volume saline irrigation vs Povidone-iodine solution cleaning of the intraoperative incision wound in preventing superficial surgical site infections in patients undergoing emergency laparotomies. The main question it aims to answer are:\n\n* Incidence of SSI after intervention\n* Length of hospital stay\n\nParticipants will be randomly assigned to two groups receiving either of the two groups:\n\nGroup A: 1000ml of IOWI with saline solution prior to incision closure Group B: The incisional wound will be closed conventionally without irrigation.\n\nResearchers will compare groups A( experimental group) and B (control group) to compare the incidence of superficial surgical site infections after intervention.",[31,202,203,204,205,206,207,32],"Surgical Wound","Surgical Incision","Emergency Laparotomies","Laparotomies","Post Operative Wound Infection","Wound Infection","2025-06-14",{"date":210,"type":61},"2025-06-18",{"date":212,"type":61},"2023-04-29",{"date":214,"type":22},"2025-12-29",{"name":216,"class":68},"Dow University of Health Sciences",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":225,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":69},"100508359","seroma-of-the-mammary-gland-100508359","NCT05899387","Seroma of the Mammary Gland","Prospective, International, Multicenter Minimal Interventional Study to Detect Possible Markers for Prediction of Seroma Development and Risk Assessment of a Breast Seroma After Mastectomy with or Without Implant-based Breast Reconstruction","SerMa","Inclusion criteria study group and control group 1:\n\n* Written informed consent\n* Age ≥ 18 years\n* all stages of DCIS or primary breast cancer (T1-T4, N0 or N+, M0) including all histopathological subtypes (ER\u002FPR positive, ER positive\u002FPR negative, Her-2\u002Fneu positive and triple negative)\n* Surgical procedure planned including ablatio or subcutaneous mastectomy with implant or expander insertion\n\nInclusion criteria control group 2 and 3:\n\n* Written informed consent\n* Age ≥ 18 years\n* Surgical procedure planned with implant or expander insertion with or without subcutaneous mastectomy\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Male sex\n* Breast cancer patients planned for breast conserving therapy\n* Recurrent breast cancer disease\n* History of breast surgery\n* Diagnosis of LCIS only\n* Pregnancy at time of diagnosis\n* Patients with a known immunodeficiency",true,{"count":227,"type":22},2000,[25],"The study is designed as international, prospective, minimal interventional study in cooperation with EUBREAST e.V. (European Breast Cancer Research Association of Surgical Trialists). Furthermore, it is planned to initiate a registry for postoperative breast seromas.",[32,231,232,233],"Breast Cancer","Mastectomy","Breast Implant; Complications","2025-02-25",{"date":236,"type":61},"2025-02-28",{"date":238,"type":61},"2024-04-01",{"date":240,"type":22},"2027-07-01",{"name":242,"class":68},"University Hospital Augsburg",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":106,"minAge":4,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":69},"100511585","fixation-of-skin-flaps-after-mastectomy-using-running-or-interrupted-sutures-for-combatting-seroma-100511585","NCT05941351","fixAtion of skiN Flaps After Mastectomy Using ruNning or Interrupted suturEs for Combatting Seroma","ANNIE","Inclusion Criteria:\n\n* Female sex.\n* 18 years or older.\n* Indication for mastectomy.\n\nExclusion Criteria:\n\n* Patients undergoing breast conserving therapy\n* Patients undergoing direct breast reconstruction\n* Patients undergoing modified radical mastectomy\n* Unable to comprehend implications and extent of study and sign for informed consent",{"count":251,"type":22},361,[25],"Rationale: Flap fixation significantly reduces the incidence of seroma formation after mastectomy. Therefore, research should focus on finding the most optimal way to secure the skin flaps to the pectoral muscle. Previous studies have compared running sutures, interrupted sutures and tissue glue application to conventional wound closure. A recent systematic review with network meta-analysis indicated running sutures as the most optimal technique, however direct comparisons and high quality articles were lacking.\n\nObjective: This prospective trial aims to directly compare running sutures with interrupted sutures in order to prevent complications in patients undergoing a mastectomy.\n\nStudy design: This trial will combine a retrospective cohort from the previous SARA-trial in Zuyderland MC with a randomised prospective trial. This study design was chosen to acquire a sample size with sufficient power and the ability to conduct this study in an acceptable time frame.\n\nStudy population: A retrospective cohort of patients participating in the SARA trial (RCT) and a prospective cohort of patients undergoing a mastectomy for breast cancer.\n\nIntervention: Group 1: Flap fixation after mastectomy with running sutures. Group 2: Flap fixation after mastectomy with interrupted sutures.\n\nMain study parameters\u002Fendpoints: The primary endpoint is the incidence of complications requiring interventions in both groups, including clinically significant seroma, infections and bleeding complications. Secondarily, the length of the procedure and cosmetic results will be compared.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: When participating, patients will undergo 3 additional outpatient clinic visits. Study visits will be combined with regular visits where possible, including the first postoperative visit after 7-10 days and either the 6 week or 3 month visit.",[32],"2023-07-03",{"date":257,"type":61},"2023-07-12",{"date":259,"type":22},"2025-01-01",{"date":261,"type":22},"2027-03-01",{"name":263,"class":68},"Zuyderland Medisch Centrum"]